Royce & Associates LP Makes A New $407,000 Investment In LeMaitre Vascular, Inc. (NASDAQ:LMAT)


Royce & Associates LP acquired a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Rating ) in the 1st quarter, according to its most recent filing with the SEC. The fund acquired 8,757 shares of the medical instruments supplier’s stock, valued at approximately $407,000.

Several other large investors also recently bought and sold shares of the company. Conestoga Capital Advisors LLC raised its stake in LeMaitre Vascular by 1.2% during the 1st quarter. Conestoga Capital Advisors LLC now owns 1,879,847 shares of the medical instruments supplier’s stock worth $87,357,000 after buying an additional 22,663 shares in the last quarter. Copeland Capital Management LLC lifted its holdings in shares of LeMaitre Vascular by 0.8% during the 1st quarter. Copeland Capital Management LLC now owns 1,215,005 shares of the medical instruments supplier’s stock valued at $56,461,000 after purchasing an additional 9,806 shares during the last quarter. Ranger Investment Management LP raised its holdings in shares of LeMaitre Vascular by 1.6% during the 4th quarter. Ranger Investment Management LP now owns 646,999 shares of the medical instruments supplier’s stock valued at $32,499,000 after buying an additional 10,010 shares during the last quarter. Summit Creek Advisors LLC lifted its holdings in shares of LeMaitre Vascular by 21.0% during the 4th quarter. Summit Creek Advisors LLC now owns 361,359 shares of the medical instruments supplier’s stock valued at $18,151,000 after buying an additional 62,754 shares during the last quarter. Finally, Grandeur Peak Global Advisors LLC raised its holdings in shares of LeMaitre Vascular by 0.9% during the 4th quarter. Grandeur Peak Global Advisors LLC now owns 314,076 shares of the medical instruments supplier’s stock valued at $15,776,000 after purchasing an additional 2,931 shares during the last quarter. 84.90% of the stock currently belongs to hedge funds and other institutional investors.

Changes in analyst ratings

Separately, Barrington Research decreased their target price on LeMaitre Vascular from $54.00 to $50.00 in a report on Friday, April 29th.

LeMaitre Vascular Stock Performance

LMAT opened at $53.24 on Friday. LeMaitre Vascular, Inc. it has a one year low of $38.32 and a one year high of $60.79. The stock has a market cap of $1.17 billion, a PE ratio of 52.71, a P/E/G ratio of 4.66 and a beta of 1.20. The firm’s 50-day moving average is $46.43 and its 200-day moving average is $45.13.

LeMaitre Vascular announces dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 8th. Investors of record on Thursday, August 25th will be issued a $0.125 dividend. This represents a dividend of $0.50 on an annualized basis and a yield of 0.94%. The ex-dividend date for this dividend is Wednesday, August 24th. LeMaitre Vascular’s dividend payout ratio is currently 49.51%.

LeMaitre vascular profile

(Get Rating)

LeMaitre Vascular, Inc designs, markets, sells, services and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers an angioscope, a fiber optic probe used to view the lumen of a blood vessel. embolectomy catheters to remove blood clots from arteries or veins. occluding catheters that temporarily block blood flow. perfusion catheters for injecting blood and other fluids into the vessels. and thrombectomy catheters, which have a silicone balloon to remove clots in the venous system.

See also

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trading information for LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Rating ).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)



Get news and reviews for LeMaitre Vascular Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for LeMaitre Vascular and related companies with MarketBeat.com ‘s FREE daily email newsletter.

Leave a Comment

Your email address will not be published.